➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Express Scripts
Colorcon
McKesson
AstraZeneca

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LY2140023

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for LY2140023

Trial ID Title Status Sponsor Phase Summary
NCT00149292 Study of LY2140023 in Schizophrenia Completed Eli Lilly and Company Phase 2 Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.
NCT00520923 A Study for Patients With Schizophrenia Completed Eli Lilly and Company Phase 2 The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.
NCT00845026 A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients Completed Eli Lilly and Company Phase 2 This study will assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical antipsychotic standard-of-care treatment. Lack of tolerability is defined as discontinuation due to adverse events (AEs). Patients who complete the active treatment phase will be eligible to continue to an optional 28 weeks of treatment extension phase. This extension phase will assess key safety and efficacy measures.
NCT01052103 A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms Completed Eli Lilly and Company Phase 2 The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
NCT01086748 A Study in Schizophrenia Patients Completed Eli Lilly and Company Phase 2 An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
NCT01125358 A Study in Schizophrenic Patients Terminated Eli Lilly and Company Phase 2 This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.
NCT01129674 A Long-Term, Open-Label, Study on Schizophrenia Terminated Eli Lilly and Company Phase 2/Phase 3 The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for LY2140023

Condition Name

Condition Name for
Intervention Trials
Schizophrenia 12
Healthy Volunteers 2
Healthy Participants 2
Healthy Controls 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Schizophrenia 14
Hepatic Insufficiency 1
Stress Disorders, Traumatic 1
Stress Disorders, Post-Traumatic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for LY2140023

Trials by Country

Trials by Country for
Location Trials
United States 92
Russian Federation 6
United Kingdom 6
Germany 5
Mexico 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
California 10
New York 9
Pennsylvania 6
Florida 6
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for LY2140023

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 1
Phase 2 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 14
Terminated 6
Not yet recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for LY2140023

Sponsor Name

Sponsor Name for
Sponsor Trials
Eli Lilly and Company 20
New York State Psychiatric Institute 2
National Institute of Mental Health (NIMH) 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 20
Other 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Harvard Business School
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.